RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
Status:
NOT_YET_RECRUITING
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-targeted allogeneic CAR-T cell therapy, in patients with newly diagnosed cytogenetically high-risk multiple myeloma who are ineligible or unwilling to undergo autologous stem cell transplantation (ASCT). Patients will receive lymphodepletion followed by a single infusion of RN1201 across four dose levels. Primary endpoints include incidence and severity of treatment-emergent adverse events. Secondary endpoints assess response rate and minimal residual disease (MRD) status.
Phase:
PHASE1
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital